Top 10 Trihexyphenidyl (Artane) Generic Manufacturers in United Kingdom
The market for Trihexyphenidyl, commonly known by its brand name Artane, has seen significant growth in the United Kingdom as the demand for Parkinson’s disease and other movement disorder treatments continues to rise. The global market for Parkinson’s disease drugs is projected to reach USD 10.6 billion by 2027, with a compound annual growth rate (CAGR) of 7.5% from 2020 to 2027. In the UK, the increasing prevalence of neurodegenerative diseases has pushed generic manufacturers to expand their portfolios, providing affordable options for patients. The following report details the top manufacturers of generic Trihexyphenidyl in the UK.
1. Teva UK Limited
Teva UK Limited is one of the leading generic manufacturers of Trihexyphenidyl in the UK. With a market share of approximately 20%, Teva produces millions of units annually. The company has a robust supply chain and distribution network, enabling it to maintain a significant presence in the generic pharmaceuticals sector.
2. Mylan UK
Mylan, now a part of Viatris, is a prominent player in the UK generic market for Trihexyphenidyl. The company holds about 15% of the market share and produces over 5 million tablets per year. Mylan is known for its commitment to affordability and accessibility, making its products widely available across various healthcare settings.
3. Accord Healthcare
Accord Healthcare is a rapidly growing pharmaceutical company in the UK, holding around 12% of the market share for Trihexyphenidyl. The company produces approximately 3 million units annually, focusing on high-quality manufacturing processes and competitive pricing, ensuring that patients have access to essential medications.
4. Sandoz
Sandoz, a division of Novartis, is a well-established generic drug manufacturer in the UK. With a market share close to 10%, Sandoz produces roughly 2 million units of Trihexyphenidyl each year. The company is recognized for its rigorous quality standards, contributing to its reputation as a trusted supplier in the market.
5. Actavis UK
Actavis, now part of Teva Pharmaceuticals, has made significant strides in the UK generic market, with a market share of about 8%. Producing approximately 1.5 million units of Trihexyphenidyl annually, Actavis focuses on innovation and patient-centric approaches to enhance treatment options.
6. Generics UK
Generics UK is known for supplying high-quality generics, including Trihexyphenidyl, with a market share of around 6%. The company produces around 1 million tablets per year, contributing to the overall accessibility of Parkinson’s disease treatments in the UK.
7. Cipla UK
Cipla UK has gained a foothold in the generic Trihexyphenidyl market, accounting for about 5% of the market share, with an annual production of around 900,000 units. The company is committed to improving health and well-being globally, focusing on innovative and affordable medications.
8. Sun Pharmaceutical Industries
Sun Pharma, a major global player in the pharmaceutical industry, has a presence in the UK generics market, with a share of approximately 4%. The company produces around 800,000 units of Trihexyphenidyl annually, emphasizing quality and reliability in its manufacturing practices.
9. Zydus Cadila
Zydus Cadila is emerging as a competitor in the UK market for Trihexyphenidyl, holding about 3% of the market share. The company produces approximately 700,000 units each year, and it focuses on research and development to expand its generic offerings.
10. Alvogen
Alvogen is a relatively newer player in the UK generics market, with a market share of around 2%. Producing approximately 500,000 units of Trihexyphenidyl annually, Alvogen focuses on expanding its portfolio of generic medications to meet the growing demand for affordable healthcare solutions.
Insights
The UK market for Trihexyphenidyl is characterized by increasing competition among generic manufacturers, driven by the rising prevalence of Parkinson’s disease and other movement disorders. The total market for generics in the UK is expected to grow at a CAGR of 5% through 2025, reflecting a strong demand for affordable treatment options. As more companies enter the market, price competition is likely to intensify, benefitting consumers and healthcare providers alike. Additionally, the ongoing focus on quality and compliance will be essential for manufacturers to maintain their market positions and meet regulatory standards. With a projected growth rate for the overall neurodegenerative drug market, generic manufacturers are well-positioned to capitalize on the evolving landscape.
Related Analysis: View Previous Industry Report
